Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives.

Barcellini W, Fattizzo B, Zaninoni A.

J Blood Med. 2019 Aug 8;10:265-278. doi: 10.2147/JBM.S190327. eCollection 2019.

2.

Clinical course and management of adult-onset immune-mediated cytopenia associated with Kabuki syndrome.

Cantoni S, Fattizzo B.

Eur J Intern Med. 2019 Nov;69:e3-e5. doi: 10.1016/j.ejim.2019.08.003. Epub 2019 Aug 16. No abstract available.

PMID:
31427185
3.

Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.

Fattizzo B, Levati G, Cassin R, Barcellini W.

Drugs. 2019 Aug;79(12):1305-1319. doi: 10.1007/s40265-019-01159-0. Review.

PMID:
31292909
4.

Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag.

Fattizzo B, Cavallaro F, Milesi G, Barcellini W.

Am J Hematol. 2019 Jun 6. doi: 10.1002/ajh.25550. [Epub ahead of print] No abstract available.

PMID:
31172568
5.

Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.

Fattizzo B, Kulasekararaj AG, Hill A, Benson-Quarm N, Griffin M, Munir T, Arnold L, Riley K, Ireland R, De Lavallade H, Potter V, Consonni D, Hillmen P, Mufti GJ, Barcellini W, Marsh JCW.

Haematologica. 2019 Nov;104(11):e494-e496. doi: 10.3324/haematol.2019.216374. Epub 2019 Mar 19. No abstract available.

6.

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.

Fattizzo B, Pasquale R, Carpenedo M, Cantoni S, Auteri G, Gramegna D, D'Adda M, Napolitano M, Consonni D, Ruggeri M, Siragusa S, Rossi G, Vianelli N, Barcellini W.

Haematologica. 2019 Oct;104(10):e470-e473. doi: 10.3324/haematol.2019.216804. Epub 2019 Mar 7. No abstract available.

7.

Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation.

Barcellini W, Zaninoni A, Gregorini AI, Soverini G, Duca L, Fattizzo B, Giannotta JA, Pedrotti P, Vercellati C, Marcello AP, Fermo E, Bianchi P, Cappellini MD.

Br J Haematol. 2019 May;185(3):523-531. doi: 10.1111/bjh.15811. Epub 2019 Mar 3.

PMID:
30828802
8.

Low-dose rituximab in autoimmune hemolytic anemia: 10 years after.

Fattizzo B, Zaninoni A, Pettine L, Cavallaro F, Di Bona E, Barcellini W.

Blood. 2019 Feb 28;133(9):996-998. doi: 10.1182/blood-2018-12-885228. Epub 2019 Jan 22. No abstract available.

PMID:
30670440
9.

IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.

Reda G, Cassin R, Gentile M, Mauro FR, Giannarelli D, Fattizzo B, Barbieri M, Silvestris I, Fabris S, Morabito F, Neri A, Barcellini W, Cortelezzi A.

Leukemia. 2019 Jun;33(6):1519-1522. doi: 10.1038/s41375-018-0344-1. Epub 2019 Jan 11. No abstract available.

PMID:
30635629
10.

Autoimmune hemolytic anemia, autoimmune neutropenia and aplastic anemia in the elderly.

Barcellini W, Fattizzo B, Cortelezzi A.

Eur J Intern Med. 2018 Dec;58:77-83. doi: 10.1016/j.ejim.2018.05.034. Review.

PMID:
30527923
11.

Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.

Reda G, Riva M, Fattizzo B, Cassin R, Giannarelli D, Pennisi M, Freyrie A, Cairoli R, Molteni A, Cortelezzi A.

Semin Hematol. 2018 Oct;55(4):202-208. doi: 10.1053/j.seminhematol.2018.02.005. Epub 2018 Feb 21. Review.

PMID:
30502848
12.

Current and emerging treatment options for autoimmune hemolytic anemia.

Barcellini W, Fattizzo B, Zaninoni A.

Expert Rev Clin Immunol. 2018 Oct;14(10):857-872. doi: 10.1080/1744666X.2018.1521722. Epub 2018 Oct 8. Review.

PMID:
30204521
13.

Utility of dynamic contrast-enhanced MRI to assess small bowel perfusion in paroxysmal nocturnal hemoglobinuria before and after eculizumab.

Barcellini W, Pezzetti G, Fattizzo B, Cavallaro F, De Cobelli F.

Eur J Intern Med. 2018 Nov;57:e25-e27. doi: 10.1016/j.ejim.2018.08.005. Epub 2018 Aug 17. No abstract available.

PMID:
30126686
14.

Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers.

Barcellini W, Zaninoni A, Fattizzo B, Giannotta JA, Lunghi M, Ferrari A, Leporace AP, Maschio N, Scaramucci L, Cantoni S, Chiurazzi F, Consonni D, Rossi G, De Fabritiis P, Gaidano G, Zanella A, Cortelezzi A.

Am J Hematol. 2018 Sep;93(9):E243-E246. doi: 10.1002/ajh.25212. Epub 2018 Aug 25. No abstract available.

15.

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.

Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D'Adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W.

Blood. 2018 Aug 2;132(5):547-550. doi: 10.1182/blood-2018-03-835413. Epub 2018 Jun 13. No abstract available.

PMID:
29898955
16.

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.

Reda G, Fattizzo B, Cassin R, Mattiello V, Tonella T, Giannarelli D, Massari F, Cortelezzi A.

J Hematol Oncol. 2018 Jun 11;11(1):79. doi: 10.1186/s13045-018-0626-0.

17.

Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients.

Barcellini W, Scola E, Lanfranconi S, Grottaroli M, Binda F, Fattizzo B, Zaninoni A, Valcamonica G, Cinnante CM, Boschetti C, Buoli M, Altamura CA, Bresolin N, Triulzi F, Zanella A, Cortelezzi A.

Sci Rep. 2018 Jan 11;8(1):476. doi: 10.1038/s41598-017-18936-0.

18.

Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.

Reda G, Cassin R, Artoni A, Fattizzo B, Lecchi A, La Marca S, Bucciarelli P, Levati GV, Peyvandi F, Cortelezzi A.

Br J Haematol. 2018 Dec;183(5):825-828. doi: 10.1111/bjh.15052. Epub 2018 Jan 7. No abstract available.

PMID:
29315493
19.

Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia.

Fattizzo B, Zaninoni A, Gianelli U, Zanella A, Cortelezzi A, Kulasekararaj AG, Barcellini W.

Am J Hematol. 2018 Aug;93(4):E88-E91. doi: 10.1002/ajh.25020. Epub 2018 Jan 10. No abstract available.

20.

Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications.

Fracchiolla NS, Fattizzo B, Cortelezzi A.

Stem Cells Int. 2017;2017:6720594. doi: 10.1155/2017/6720594. Epub 2017 Aug 21. Review.

21.

Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for.

Fracchiolla NS, Iurlo A, Ferla V, Fattizzo B, Freyrie A, Reda G, Cortelezzi A.

Clin Lab. 2017 Sep 1;63(9):1513-1517. doi: 10.7754/Clin.Lab.2017.170322.

22.

Paroxysmal nocturnal hemoglobinuria with spontaneous clinical remission.

Ferla V, Zaninoni A, Fattizzo B, Fermo E, Gianelli U, Barcellini W.

Eur J Intern Med. 2017 Sep;43:e11-e14. doi: 10.1016/j.ejim.2017.04.011. Epub 2017 May 18. No abstract available.

PMID:
28528998
23.

Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report.

Reda G, Fattizzo B, Cassin R, Flospergher E, Orofino N, Gianelli U, Barcellini W, Cortelezzi A.

Oncol Lett. 2017 Mar;13(3):1307-1310. doi: 10.3892/ol.2016.5549. Epub 2016 Dec 28.

24.

Chronic lymphocytic leukemia and prognostic models: A bridge between clinical and biological markers.

Reda G, Cassin R, Fattizzo B, Giannarelli D, Mattiello V, Barcellini W, Cortelezzi A.

Am J Hematol. 2017 Jul;92(7):E135-E137. doi: 10.1002/ajh.24755. Epub 2017 May 26. No abstract available.

25.

Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes.

Barcellini W, Fattizzo B, Zaninoni A, Valli V, Ferri V, Gianelli U, Cortelezzi A.

Am J Hematol. 2017 Mar;92(3):E26-E29. doi: 10.1002/ajh.24618. Epub 2017 Feb 3. No abstract available.

26.

Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.

Marangon M, Vianelli N, Palandri F, Mazzucconi MG, Santoro C, Barcellini W, Fattizzo B, Volpetti S, Lucchini E, Polverelli N, Carpenedo M, Isola M, Fanin R, Zaja F.

Eur J Haematol. 2017 Apr;98(4):371-377. doi: 10.1111/ejh.12839. Epub 2017 Jan 20.

PMID:
27981682
27.

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) role in hematopoiesis and in hematologic diseases: A critical review.

Fracchiolla NS, Annaloro C, Guidotti F, Fattizzo B, Cortelezzi A.

Toxicology. 2016 Dec 30;374:60-68. doi: 10.1016/j.tox.2016.10.007. Epub 2016 Oct 17. Review.

PMID:
27765685
28.

Biological and molecular characterization of a rare case of cutaneous Richter syndrome.

Reda G, Cassin R, Fabris S, Ciceri G, Fattizzo B, Sciumè M, Orofino N, Gianelli U, Neri A, Cortelezzi A.

Hematol Oncol. 2017 Dec;35(4):869-874. doi: 10.1002/hon.2327. Epub 2016 Jul 12.

PMID:
27400669
29.

Reduced 25-OH vitamin D in patients with autoimmune cytopenias, clinical correlations and literature review.

Fattizzo B, Zaninoni A, Giannotta JA, Binda F, Cortelezzi A, Barcellini W.

Autoimmun Rev. 2016 Jul;15(7):770-5. doi: 10.1016/j.autrev.2016.03.015. Epub 2016 Mar 14. Review.

PMID:
26988993
30.

Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.

Reda G, Orofino N, Cassin R, Sciumè M, Fattizzo B, Cortelezzi A.

Expert Opin Drug Saf. 2016 Jun;15(6):865-73. doi: 10.1517/14740338.2016.1165665. Epub 2016 Apr 7. Review.

PMID:
26967902
31.

Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia.

Barcellini W, Fattizzo B.

Dis Markers. 2015;2015:635670. doi: 10.1155/2015/635670. Epub 2015 Dec 27. Review.

32.

Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis.

Zaninoni A, Vercellati C, Imperiali FG, Marcello AP, Fattizzo B, Fermo E, Bianchi P, Grossi C, Cattaneo A, Cortelezzi A, Zanella A, Barcellini W.

Transfusion. 2015 Dec;55(12):2930-8. doi: 10.1111/trf.13257. Epub 2015 Aug 10.

PMID:
26259504
33.

Is chronic neutropenia always a benign disease? Evidences from a 5-year prospective study.

Fattizzo B, Zaninoni A, Consonni D, Zanella A, Gianelli U, Cortelezzi A, Barcellini W.

Eur J Intern Med. 2015 Oct;26(8):611-5. doi: 10.1016/j.ejim.2015.05.019. Epub 2015 Jun 8.

PMID:
26066399
34.

Anemia and splenomegaly: what lies behind?

Migone De Amicis M, Fattizzo B, Poggiali E, Minonzio F, Gianelli U, Cappellini MD.

Intern Emerg Med. 2015 Sep;10(6):711-4. doi: 10.1007/s11739-015-1254-0. Epub 2015 May 19. No abstract available.

PMID:
25986481
35.

Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias.

Fattizzo B, Zaninoni A, Nesa F, Sciumbata VM, Zanella A, Cortelezzi A, Barcellini W.

Am J Hematol. 2015 Aug;90(8):E149-51. doi: 10.1002/ajh.24047. No abstract available.

36.

Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia.

Fattizzo B, Radice T, Cattaneo D, Pomati M, Barcellini W, Iurlo A.

Clin Lab. 2014;60(11):1929-32.

PMID:
25648037
37.

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.

Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A.

Blood. 2014 Nov 6;124(19):2930-6. doi: 10.1182/blood-2014-06-583021. Epub 2014 Sep 16.

PMID:
25232059
38.

Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression.

Barcellini W, Imperiali FG, Zaninoni A, Reda G, Consonni D, Fattizzo B, Lonati S, Nobili L, Zanella A, Cortelezzi A.

Leuk Lymphoma. 2014 Aug;55(8):1768-73. doi: 10.3109/10428194.2013.856426. Epub 2014 Feb 14.

PMID:
24144314
39.

Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns.

Barcellini W, Iurlo A, Radice T, Imperiali FG, Zaninoni A, Fattizzo B, Guidotti F, Bianchi P, Fermo E, Consonni D, Cortelezzi A.

Leuk Res. 2013 Nov;37(11):1509-15. doi: 10.1016/j.leukres.2013.09.001. Epub 2013 Sep 12.

PMID:
24080022
40.

Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia.

Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Di Bona E, Fattizzo B, Consonni D, Cortelezzi A, Zanella A.

Eur J Haematol. 2013 Dec;91(6):546-51. doi: 10.1111/ejh.12199. Epub 2013 Oct 3.

PMID:
24033754
41.

Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies.

Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, Fattizzo B, Consonni D, Cortelezzi A, Fanin R, Zanella A.

Blood. 2012 Apr 19;119(16):3691-7. doi: 10.1182/blood-2011-06-363556. Epub 2012 Jan 20.

PMID:
22267606

Supplemental Content

Loading ...
Support Center